Satralizumab
Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD).[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | interleukin 6 receptor |
| Clinical data | |
| Trade names | Enspryng |
| Other names | SA237, sapelizumab |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6340H9776N1684O2022S46 |
| Molar mass | 143416.47 g·mol−1 |
This drug is being developed by Chugai Pharmaceutical, a member of the Roche Group.[2] The efficacy and safety of Satralizumab has been tested in two phase III clinical trials in patients with diagnosed neuromyelitis optica.[3]
Satralizumab has been approved for the treatment of AQP4-IgG-seropositive NMOSD in Canada, Japan, and Switzerland.[4]
Names
Satralizumab is the International Nonproprietary Name (INN)[5]
References
- Statement On A Nonproprietary Name Adopted By The USAN Council - Satralizumab, American Medical Association.
- "Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018".
- "compendium.ch". compendium.ch (in German). 2020-07-08. Retrieved 2020-08-10.
- "Enspryng (satralizumab)". Roche. Retrieved 9 August 2020.
- World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3): 552. hdl:10665/330961. License: CC BY-NC-SA 3.0 IGO.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.